Amyloid β and tau are involved in sleep disorder in Alzheimer's disease by orexin A and adenosine A(1) receptor

Liu,Zhenhua; Wang,Fumin; Tang,Minglu; Zhao,Yongjun; Wang,Xiaoting

doi:10.3892/ijmm.2018.3935

Amyloid β and tau are involved in sleep disorder in Alzheimer's disease by orexin A and adenosine A(1) receptor

Authors:
- Zhenhua Liu
- Fumin Wang
- Minglu Tang
- Yongjun Zhao
- Xiaoting Wang
View Affiliations

Affiliations: Department of Sleep Medicine Center, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong 250021, P.R. China
Published online on: October 16, 2018 https://doi.org/10.3892/ijmm.2018.3935
Pages: 435-442

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Sleep disorder is confirmed as a core component of Alzheimer's disease (AD), while the accumulation of amyloid β (Aβ) in brain tissue is an important pathological feature of AD. However, how Aβ affects AD‑associated sleep disorder is not yet well understood. In the present study, experiments on animal and cell models were performed to detect the association between sleep disorder and Aβ. It was observed that Aβ25‑35 administration significantly decreased non‑rapid eye movement sleep, while it increased wakefulness in mice. In addition, reverse transcription‑quantitative polymerase chain reaction and western blot analysis revealed that the expression levels of tau, p‑tau, orexin A and orexin neurons express adenosine A1 receptor (A1R) were markedly upregulated in the brain tissue of AD mice compared with that in samples obtained from control mice. Furthermore, the in vitro study revealed that the expression levels of tau, p‑tau, orexin A and adenosine A1R were also significantly increased in human neuroblastoma SH‑SY5Y cells treated with Aβ25‑35 as compared with the control cells. In addition, the tau inhibitor TRx 0237 significantly reversed the promoting effects of Aβ25‑35 on tau, p‑tau, orexin A and adenosine A1R expression levels, and adenosine A1R or orexin A knockdown also inhibited tau and p‑tau expression levels mediated by Aβ25‑35 in AD. These results indicate that Aβ and tau may be considered as novel biomarkers of sleep disorder in AD pathology, and that they function by regulating the expression levels of orexin A and adenosine A1R.

View Figures

View References

1	Brookmeyer R, Johnson E, Ziegler-Graham K and Arrighi HM: Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 3:186–191. 2007. View Article : Google Scholar : PubMed/NCBI
2	Moran M, Lynch CA, Walsh C, Coen R, Coakley D and Lawlor BA: Sleep disturbance in mild to moderate Alzheimer’s disease. Sleep Med. 6:347–352. 2005. View Article : Google Scholar : PubMed/NCBI
3	Kondratova AA and Kondratov RV: The circadian clock and pathology of the ageing brain. Nat Rev Neurosci. 13:325–335. 2012. View Article : Google Scholar : PubMed/NCBI
4	Ooms S, Overeem S, Besse K, Rikkert MO, Verbeek M and Claassen JA: Effect of 1 night of total sleep deprivation on cerebrospinal fluid β-amyloid 42 in healthy middle-aged men: A randomized clinical trial. JAMA Neurol. 71:971–977. 2014. View Article : Google Scholar : PubMed/NCBI
5	Peter-Derex L, Magnin M and Bastuji H: Heterogeneity of arousals in human sleep: A stereo-electroencephalographic study. Neuroimage. 123:229–244. 2015. View Article : Google Scholar : PubMed/NCBI
6	Mander BA, Winer JR, Jagust WJ and Walker MP: Sleep: A novel mechanistic pathway, biomarker, and treatment target in the pathology of Alzheimer’s disease? Trends Neurosci. 39:552–566. 2016. View Article : Google Scholar : PubMed/NCBI
7	Hyman BT: New neuropathological criteria for Alzheimer disease. Arch Neurol. 55:1174–1176. 1998. View Article : Google Scholar : PubMed/NCBI
8	Tanaka T, Mayuyama D and Takeda M: Alzheimer disease and tau protein. Rinsho Shinkeigaku. 52:1171–1173. 2012.In Japanese. View Article : Google Scholar
9	Campbell SS and Murphy PJ: Delayed sleep phase disorder in temporal isolation. Sleep. 30:1225–1228. 2007. View Article : Google Scholar : PubMed/NCBI
10	Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S and Holtzman DM: Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science. 326:1005–1007. 2009. View Article : Google Scholar : PubMed/NCBI
11	Morishima-Kawashima M and Ihara Y: Alzheimer’s disease: Beta-amyloid protein and tau. J Neurosci Res. 70:392–401. 2002. View Article : Google Scholar : PubMed/NCBI
12	Vyazovskiy VV, Olcese U, Lazimy YM, Faraguna U, Esser SK, Williams JC, Cirelli C and Tononi G: Cortical firing and sleep homeostasis. Neuron. 63:865–878. 2009. View Article : Google Scholar : PubMed/NCBI
13	de Lecea L, Kilduff TS, Peyron C, Gao X, Foye PE, Danielson PE, Fukuhara C, Battenberg EL, Gautvik VT, Bartlett FS II, et al: The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity. Proc Natl Acad Sci USA. 95:322–327. 1998. View Article : Google Scholar : PubMed/NCBI
14	Sakurai T, Amemiya A, Ishii M, Matsuzaki I, Chemelli RM, Tanaka H, Williams SC, Richardson JA, Kozlowski GP, Wilson S, et al: Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell. 92:573–585. 1998. View Article : Google Scholar : PubMed/NCBI
15	Liguori C: Orexin And Alzheimer’s disease. Curr Top Behav Neurosci. 33:305–322. 2017. View Article : Google Scholar
16	Thakkar MM, Winston S and McCarley RW: Orexin neurons of the hypothalamus express adenosine A1 receptors. Brain Res. 944:190–194. 2002. View Article : Google Scholar : PubMed/NCBI
17	Thakkar MM, Engemann SC, Walsh KM and Sahota PK: Adenosine and the homeostatic control of sleep: Effects of A1 receptor blockade in the perifornical lateral hypothalamus on sleep-wakefulness. Neuroscience. 153:875–880. 2008. View Article : Google Scholar : PubMed/NCBI
18	Alam MN, Kumar S, Rai S, Methippara M, Szymusiak R and McGinty D: Role of adenosine A₁ receptor in the perifornical-lateral hypothalamic area in sleep-wake regulation in rats. Brain Res. 1304:96–104. 2009. View Article : Google Scholar : PubMed/NCBI
19	Cedernaes J, Osorio RS, Varga AW, Kam K, Schiöth HB and Benedict C: Candidate mechanisms underlying the association between sleep-wake disruptions and Alzheimer’s disease. Sleep Med Rev. 31:102–111. 2017. View Article : Google Scholar
20	Gu L, Wu D, Tang X, Qi X, Li X, Bai F, Chen X, Ren Q and Zhang Z: Myelin changes at the early stage of 5XFAD mice. Brain Res Bull. 137:285–293. 2018. View Article : Google Scholar
21	Aytan N, Choi JK, Carreras I, Crabtree L, Nguyen B, Lehar M, Blusztajn JK, Jenkins BG and Dedeoglu A: Protective effects of 7,8-dihydroxyflavone on neuropathological and neurochemical changes in a mouse model of Alzheimer’s disease. Eur J Pharmacol. 828:9–17. 2018. View Article : Google Scholar : PubMed/NCBI
22	Maiti P, Paladugu L and Dunbar GL: Solid lipid curcumin particles provide greater anti-amyloid, anti-inflammatory and neuroprotective effects than curcumin in the 5xFAD mouse model of Alzheimer’s disease. BMC Neurosci. 19:72018. View Article : Google Scholar
23	Shao J, Lin M, Li Y, Li X, Liu J, Liang J and Yao H: In vivo blood glucose quantification using Raman spectroscopy. PLoS One. 7:e481272012. View Article : Google Scholar : PubMed/NCBI
24	Harkany T, Abrahám I, Kónya C, Nyakas C, Zarándi M, Penke B and Luiten PG: Mechanisms of beta-amyloid neurotoxicity: Perspectives of pharmacotherapy. Rev Neurosci. 11:329–382. 2000. View Article : Google Scholar : PubMed/NCBI
25	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2^−ΔΔ^C^T method. Methods. 25:402–408. 2001. View Article : Google Scholar
26	Kantarci K: Molecular imaging of Alzheimer disease pathology. AJNR Am J Neuroradiol. 35(Suppl 6): S12–S17. 2014. View Article : Google Scholar : PubMed/NCBI
27	Guo K, Yin G, Zi XH, Zhu HX and Pan Q: Effect of selective serotonin reuptake inhibitors on expression of 5-HT1AR and neurotransmitters in rats with vascular dementia. Genet Mol Res. 15: View Article : Google Scholar : 2016.PubMed/NCBI
28	Liu ZJ, Li ZH, Liu L, Tang WX, Wang Y, Dong MR and Xiao C: Curcumin attenuates beta-amyloid-induced neuroinlammation via activation of peroxisome proliferator-activated receptor-gamma function in a rat model of Alzheimer’s disease. Front Pharmacol. 7:2612016. View Article : Google Scholar
29	Helal M, Hingant E, Pujo-Menjouet L and Webb GF: Alzheimer’s disease: Analysis of a mathematical model incorporating the role of prions. J Math Biol. 69:1207–1235. 2014. View Article : Google Scholar
30	McCurry SM, Logsdon RG, Vitiello MV and Teri L: Treatment of sleep and nighttime disturbances in Alzheimer’s disease: A behavior management approach. Sleep Med. 5:373–377. 2004. View Article : Google Scholar : PubMed/NCBI
31	Vitiello MV and Prinz PN: Alzheimer’s disease. Sleep and sleep/wake patterns. Clin Geriatr Med. 5:289–299. 1989. View Article : Google Scholar : PubMed/NCBI
32	Rosenwasser AM: Functional neuroanatomy of sleep and circadian rhythms. Brain Res Rev. 61:281–306. 2009. View Article : Google Scholar : PubMed/NCBI
33	Arriagada PV, Growdon JH, Hedley-Whyte ET and Hyman BT: Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology. 42:631–639. 1992. View Article : Google Scholar : PubMed/NCBI
34	Braak H and Braak E: Neuropathological stageing of Alzheimer- related changes. Acta Neuropathol. 82:239–259. 1991. View Article : Google Scholar
35	Saper CB, Scammell TE and Lu J: Hypothalamic regulation of sleep and circadian rhythms. Nature. 437:1257–1263. 2005. View Article : Google Scholar : PubMed/NCBI
36	Arrigoni E, Mochizuki T and Scammell TE: Activation of the basal forebrain by the orexin/hypocretin neurones. Acta Physiol. 198:223–235. 2010. View Article : Google Scholar
37	Lee MG, Hassani OK and Jones BE: Discharge of identified orexin/hypocretin neurons across the sleep-waking cycle. J Neurosci. 25:6716–6720. 2005. View Article : Google Scholar : PubMed/NCBI
38	Di Meco A, Lauretti E, Vagnozzi AN and Praticò D: Zileuton restores memory impairments and reverses amyloid and tau pathology in aged Alzheimer’s disease mice. Neurobiol Aging. 35:2458–2464. 2014. View Article : Google Scholar : PubMed/NCBI